Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing transformative genome-edited allogeneic cell therapies for treating devastating human diseases. Utilizing next-generation CRISPR genome-editing technologies, including their proprietary chRDNA (CRISPR hybrid RNA-DNA) technology, Caribou is at the forefront of precision genome editing. Their technologies allow for complex genome editing with superior specificity and precision, such as multiplex gene knockout and insertion while maintaining genomic integrity. Caribou is pioneering off-the-shelf CAR-T cell therapies from healthy donor cells to address limitations of current therapies. They use their cutting-edge technologies to enhance the effectiveness of cell therapies through strategies like checkpoint disruption and immune cloaking. Co-founded by Jennifer Doudna, a Nobel Prize recipient, Caribou Biosciences is recognized as a leader in the CRISPR field.